C4 Therapeutics, Inc. (CCCC) — Stock Score Summary

C4 Therapeutics, Inc. (CCCC) has a MoatMap StockRank of 46/100 based on Quality (31/100), Value (39/100), and Momentum (63/100) factor scores. The current signal is HOLD. C4 Therapeutics is a pre-revenue biotechnology firm specializing in targeted protein degradation. It is highly speculative, cash-burning, and does not meet the Terry Smith or Warren Buffett criteria for positive cash flow and proven business models.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degraders (TPDs) to treat diseases, primarily in oncology and immunology. As a pioneer in the burgeoning field of TPDs, the company leverages its proprietary TORPEDO platform to design highly selective and potent small molecule degraders. C4 Therapeutics is a leading innovator in targeted protein degradation, aiming to revolutionize drug discovery with this novel therapeutic modality.

Key Financial Metrics

Price$3.58
Market Cap$405M
P/E (Forward)-3.60
Price/Book1.85
Return on Equity-48.3%
Return on Invested Capital-32.0%
Debt/Equity24.95
Gross Margin74.2%
Operating Margin-451.6%
Revenue Growth-15.0%
Free Cash Flow$-51M

C4 Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is C4 Therapeutics, Inc.’s (CCCC) StockRank?
MoatMap’s StockRank for C4 Therapeutics, Inc. (CCCC) is 46/100, with a Hold signal. It is a composite of Quality (31), Value (39), and Momentum (63) factor ranks across MoatMap’s 19,000+ stock universe.
Does C4 Therapeutics, Inc. have an economic moat?
C4 Therapeutics, Inc. (CCCC) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is C4 Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for C4 Therapeutics, Inc. (CCCC) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is C4 Therapeutics, Inc. in?
C4 Therapeutics, Inc. (CCCC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCCCC deep dive reportAI ChampionsHow we score stocksSense-check another stock